Please login to the form below

Not currently logged in
Email:
Password:

Purdue Pharma

This page shows the latest Purdue Pharma news and features for those working in and with pharma, biotech and healthcare.

Endo faces industry-first FDA call to pull its opioid painkiller

Endo faces industry-first FDA call to pull its opioid painkiller

Previously Purdue Pharma’s opioid painkiller Oxycontin was removed from the market when an abuse-resistant form became available, but the privately-held pharmaceutical company removed the drug from the market

Latest news

  • FDA panel backs Pfizer and Teva abuse-resistant painkillers FDA panel backs Pfizer and Teva abuse-resistant painkillers

    The two products are aimed at a market estimated to be worth around $2.5bn with several abuse-resistant products already on the market including Purdue Pharma's Hysingla ER and

  • Purdue gets FDA nod for abuse-deterrent painkiller Purdue gets FDA nod for abuse-deterrent painkiller

    Purdue gets FDA nod for abuse-deterrent painkiller. Around 105 people per day die from a drug overdose in the US. ... Purdue Pharma has expanded its portfolio of opioid analgesic drugs following FDA approval of Hysingla ER, a once-daily product designed

  • FDA approves pain drug that has reduced risk of abuse FDA approves pain drug that has reduced risk of abuse

    FDA approves pain drug that has reduced risk of abuse. Purdue’ s Targiniq ER developed to deter snorting and injection. ... Purdue Pharma, the company behind Targiniq ER, has developed the drug to deter, but not totally prevent, such abuse under new

  • A will of iron A will of iron

    Ad Lib blog. Creative critiques of pharma and healthcare ads and campaigns. ... OxyContin – Purdue Pharma. Author. Public.

  • FDA bars generic version of Purdue’s painkiller OxyContin FDA bars generic version of Purdue’s painkiller OxyContin

    FDA bars generic version of Purdue’ s painkiller OxyContin. New abuse-deterrent formulation means original version no longer has positive benefit-to-risk profile. ... US regulators have banned generic versions of Purdue Pharma's painkiller OxyContin

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    825. Exicure (US). Purdue Pharma (US). Research collaboration &options. Spherical Nucleic Acid (SNA) technology for discovery and development of psoriasis treatment; option to AST-005. ... and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure

  • Pharma deals in September 2015 Pharma deals in September 2015

    Let's deal with the pain first …. After last month's deal with Eisai for lemborexant, a phase III insomnia treatment, Purdue Pharma is refocusing on its pain portfolio by ... Collaboration - public private partnership. 220. VM Pharma. Purdue Pharma.

  • Pharma deals during December 2012 Pharma deals during December 2012

    Pharma deals during December 2012. Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month. ... What perhaps is a mystery is why Titan made this deal with a newly formed marketing company rather than Purdue Pharma, a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Purdue Pharma appoints Dr Craig Landau as its CEO Purdue Pharma appoints Dr Craig Landau as its CEO

    Purdue Pharma appoints Dr Craig Landau as its CEO. He also takes up president role. ... He succeeds Mark Timey who leaves Purdue Pharma to “pursue other career opportunities”.

  • McCann Health expands consulting team McCann Health expands consulting team

    various sales and marketing positions at Johnson &Johnson, Purdue Pharma and Bristol-Myers Squibb.

  • Purdue Pharma appoints Dr Alan Dunton Purdue Pharma appoints Dr Alan Dunton

    Purdue Pharma appoints Dr Alan Dunton. He joins the pain specialist as senior VP of research and development. ... Purdue Pharma has appointed Dr Alan Dunton as senior vice president of research and development in a role that also sees him join its

  • Purdue looks to Merck for new CEO Purdue looks to Merck for new CEO

    Purdue looks to Merck for new CEO. Mark Timney will lead pain specialist. ... Purdue Pharma has appointed Merck &Co veteran Mark Timney as CEO, replacing John Stewart who retires.

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics